03-20-2008: Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will
provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for advanced bowel cancer Vectibix(r) (panitumumab). It is the first time that the European Commission has licensed a bowel cancer product with the stipulation that a predictive test should be carried out. The Lab 21 test was developed by DxS Ltd, a developer of biomarker assays and companion diagnostics for targeted cancer therapies.
Introduced to the UK earlier this year, Vectibix is currently licensed for patients with metastatic bowel cancer for whom standard chemotherapy has failed in patients with a specific gene mutation. In a biomarker analysis of the pivotal clinical trial, the drug doubled median progression-free survival in patients with non-mutated (wild type) KRAS (Kirsten Rat Sarcoma 2 viral oncogene homologue) compared with patients receiving best supportive care alone.
Amgen scientists had discovered that only those patients with the non-mutated (wild type) KRAS would respond to Vectibix. Patients with metastatic bowel cancer will be tested for the presence of the wild type KRAS gene before they are prescribed the drug. Approximately 60 per cent of patients with advanced bowel cancer have wild type KRAS. Of these, up to 60 per cent would be expected to respond to Vectibix.
Predictive genetic test for bowel cancer treatment is introduced in the UK
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for ... more
Graffinity and Amgen enter into drug discovery research agreement
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets ... more
Galapagos expands and extends drug discovery collaboration with Amgen into 2008
Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically- ... more
Lab21 Wins Biomedical Project of the Year Award
Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line. The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem. Lab21’s MycAssay Aspergi ... more
Lab21 Announces Positive Results for Aspergillus Detection in Critical Care and Haematology Patients
Lab21 Limited has announced the completion of an evaluation of a commercial PCR test, its MycAssayTM Aspergillus assay, to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness. The prospective evaluation was performed by ... more
Lab21 Extends CPA Accreditation
Lab21 Limited has announced that its Clinical Laboratory Division has extended its Clinical Pathology Accreditation (CPA) scope to include Molecular Biology and Virology in addition to Biochemistry. The accreditation was awarded by Clinical Pathology Accreditation (UK), the quality assuranc ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
